ADMA Biologics reports second quarter 2026 results as ASCENIV revenue climbs 24%
ADMA reiterated full-year 2026 guidance and said its SG-001 preclinical program remains on track for a pre-IND meeting package submission to the FDA by year-end.
SEC filing